Ownership history in DCF Advisers, LLC Β· 12 quarters on record
This page tracks every 13F SEC filing in which DCF Advisers, LLC reported a position in LIFECORE BIOMEDICAL INC (LFCR). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π DCF Advisers, LLC underperformed the S&P 500 by β17.3% annually on this LFCR position. Timing score: 18% (2/11 decisions correct). Average cost basis: $7.38. Maximum drawdown during holding period: β49.0%.
β Significantly underperformed the S&P 500 by 17.3% ann.
11 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
2 of 11 add/trim decisions correct
Best entry: $5.13 (2024 Q2) Β· Worst: $9.67 (2023 Q2)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
6 adds Β· 6 trims. Bought during 4 of 7 down-price quarters. π More buys than sells across the holding period.
π Portfolio weight has been declining in recent quarters. Possible distribution phase.
Currently 0.97% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size